Click‐Chemistry‐Mediated Cell Membrane Glycopolymer Engineering to Potentiate Dendritic Cell Vaccines DOI Open Access
Yang He, Zijian Xiong,

Xingyu Heng

et al.

Angewandte Chemie International Edition, Journal Year: 2023, Volume and Issue: 63(2)

Published: Nov. 29, 2023

Abstract Dendritic cell vaccine (DCV) holds great potential in tumor immunotherapy owing to its potent ability eliciting tumor‐specific immune responses. Aiming at engineering enhanced DCV, we report the first effort construct a glycopolymer‐engineered DC (G‐DCV) via metabolicglycoengineering and copper‐free click‐chemistry. Model G‐DCV was prepared by firstly delivering antigens, ovalbumin (OVA) into dendritic cells (DC) with fluoroalkane‐grafted polyethyleneimines, followed conjugating glycopolymers terminal group of dibenzocyclooctyne (DBCO) onto cells. Compared unmodified our could induce stronger T activation due adhesion between DCs Notably, such more effectively inhibit growth mouse B16‐OVA (expressing OVA antigen) model after adoptive transfer. Moreover, combination an checkpoint inhibitor, showed further increased anti‐tumor effects treating different models. Thus, work provides novel strategy enhance therapeutic effectiveness vaccines.

Language: Английский

The quest for nanoparticle-powered vaccines in cancer immunotherapy DOI Creative Commons
Zhe Sun,

Hui Zhao,

Li Ma

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Feb. 14, 2024

Abstract Despite recent advancements in cancer treatment, this disease still poses a serious threat to public health. Vaccines play an important role preventing illness by preparing the body's adaptive and innate immune responses combat diseases. As our understanding of malignancies their connection system improves, there has been growing interest priming fight more effectively comprehensively. One promising approach involves utilizing nanoparticle systems for antigen delivery, which shown potentiate as vaccines and/or adjuvants. In review, we comprehensively summarized immunological mechanisms while focusing specifically on applications various types nanoparticles field immunotherapy. By exploring these breakthroughs, hope identify significant challenges obstacles making nanoparticle-based adjuvants feasible clinical application. This review serves assess breakthroughs vaccinations shed light prospects potential barriers. doing so, aim inspire future immunotherapies that harness nanotechnology deliver effective targeted treatments. Graphical abstract

Language: Английский

Citations

27
Cancer Nanovaccines: Nanomaterials and Clinical Perspectives DOI
Nimeet Desai, Vivek P. Chavda, Thakur Raghu Raj Singh

et al.

Small, Journal Year: 2024, Volume and Issue: 20(35)

Published: May 1, 2024

Abstract Cancer nanovaccines represent a promising frontier in cancer immunotherapy, utilizing nanotechnology to augment traditional vaccine efficacy. This review comprehensively examines the current state‐of‐the‐art nanovaccine development, elucidating innovative strategies and technologies employed their design. It explores both preclinical clinical advancements, emphasizing key studies demonstrating potential elicit robust anti‐tumor immune responses. The study encompasses various facets, including integrating biomaterial‐based nanocarriers for antigen delivery, adjuvant selection, impact of nanoscale properties on performance. Detailed insights into complex interplay between tumor microenvironment responses are provided, highlighting challenges opportunities optimizing therapeutic outcomes. Additionally, presents thorough analysis ongoing trials, presenting snapshot landscape. By curating latest scientific findings developments, this aims serve as comprehensive resource researchers clinicians engaged advancing immunotherapy. Integrating design holds immense promise revolutionizing treatment paradigms, provides timely update evolving landscape nanovaccines.

Language: Английский

Citations

26
Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy DOI
Xuanbo Zhang, Kaiyuan Wang, Zhiqiang Zhao

et al.

ACS Nano, Journal Year: 2024, Volume and Issue: 18(9), P. 7136 - 7147

Published: Feb. 26, 2024

Tapping into the innate immune system's power, nanovaccines can induce tumor-specific responses, which is a promising strategy in cancer immunotherapy. However, traditional vaccine design, requiring simultaneous loading of antigens and adjuvants, complex poses challenges for mass production. Here, we developed tumor nanovaccine platform that integrates adjuvant functions delivery vehicle, using branched polyguanidine (PolyGu) nanovaccines. These were produced by modifying polyethylenimine (PEI) with various guanidine groups, transforming PEI's cytotoxicity activation. The PolyGu based on poly(phenyl biguanidine ) (Poly-PBG) effectively stimulated dendritic cells, promoted their maturation

Language: Английский

Citations

18
mRNA Cancer Vaccines: Construction and Boosting Strategies DOI
Xiaoqing Liu, Pei Huang, Rusen Yang

et al.

ACS Nano, Journal Year: 2023, Volume and Issue: 17(20), P. 19550 - 19580

Published: Oct. 11, 2023

In late 2020, the U.S. Food and Drug Administration (FDA) approved a lipid-based mRNA vaccine for prevention of COVID-19, which has pushed this field to be more closely studied motivated researchers delve deeper into therapeutics. To date, research on cancer vaccines been developed rapidly, substantial hopeful therapeutic results have achieved against various solid tumors in clinical trials. review, we first introduce three main components vaccines, including antigens, adjuvants, delivery vectors. Engineering these can optimize effects vaccines. For instance, appropriate modification structure alleviate poor stability innate immunogenicity mRNA, use vectors address issues low efficiency vivo. Second, emphatically discuss some strategies further improve efficacy namely modulating immunosuppressive tumor environment, optimizing administration routes, achieving targeting intended tissues or organs, employing combination therapy. These strengthen inhibitory ability increase possibility elimination. Finally, point out challenges practice offer our perspectives future developments rapidly evolving field. It is anticipated that will therapy near future.

Language: Английский

Citations

44
NIR‐Activatable Heterostructured Nanoadjuvant CoP/NiCoP Executing Lactate Metabolism Interventions for Boosted Photocatalytic Hydrogen Therapy and Photoimmunotherapy DOI
Chunzheng Yang,

Jiashi Zhang,

Mengyu Chang

et al.

Advanced Materials, Journal Year: 2023, Volume and Issue: 36(5)

Published: Nov. 2, 2023

Near-infrared (NIR) laser-induced photoimmunotherapy has aroused great interest due to its intrinsic noninvasiveness and spatiotemporal precision, while immune evasion evoked by lactic acid (LA) accumulation severely limits clinical outcomes. Although several metabolic interventions have been devoted ameliorate immunosuppression, intracellular residual LA still remains a potential energy source for oncocyte proliferation. Herein, an immunomodulatory nanoadjuvant based on yolk-shell CoP/NiCoP (CNCP) heterostructure loaded with the monocarboxylate transporter 4 inhibitor fluvastatin sodium (Flu) is constructed concurrently relieve immunosuppression elicit robust antitumor immunity. Under NIR irradiation, CNCP heterojunctions exhibit superior photothermal performance photocatalytic production of reactive oxygen species hydrogen. The continuous heat then facilitates Flu release restrain exudation from tumor cells, whereas cumulative can be depleted as hole scavenger improve efficiency. Subsequently, potentiated therapy not only initiate systematic immunoreaction, but also provoke severe mitochondrial dysfunction disrupt supply shock protein synthesis, in turn realizing mild therapy. Consequently, remodeling endows intensive cascade treatment optimal safety profile effectually suppress proliferation metastasis, which offers new paradigm development metabolism-regulated immunotherapy.

Language: Английский

Citations

26
Injectable Nano-in-Gel Vaccine for Spatial and Temporal Control of Vaccine Kinetics and Breast Cancer Postsurgical Therapy DOI
Taiyuan Liu,

Xinghui Si,

Liping Liu

et al.

ACS Nano, Journal Year: 2024, Volume and Issue: 18(4), P. 3087 - 3100

Published: Jan. 18, 2024

Breast cancer is the most commonly diagnosed cancer, and surgical resection first choice for its treatment. With development of operation techniques, treatment breast evolving toward minimally invasive breast-conserving approaches. However, surgery prone to an increased risk recurrence becoming a key challenge that needs be solved. In this study, we introduce one-shot injectable nano-in-gel vaccine (NIGel-Vax) postoperative therapy. The NIGel-Vax was constructed by mixing protein antigens with PEI-4BImi-Man adjuvant then encapsulated in hydrogel made oxidized dextran (ODEX) 4-arm PEG-ONH2. Using 4T1 tumor-extracted proteins as antigen, achieved 92% tumor suppression rate 33% cure therapy model. tumor-associated antigen trophoblast cell-surface 2 (TROP2) 96% 50% triple-negative (TNBC) models. This design provides encouraging approach management.

Language: Английский

Citations

16
Theranostics - a sure cure for cancer after 100 years? DOI Creative Commons
Yangmeihui Song, Jianhua Zou, Ernesto Castellanos

et al.

Theranostics, Journal Year: 2024, Volume and Issue: 14(6), P. 2464 - 2488

Published: Jan. 1, 2024

Cancer has remained a formidable challenge in medicine and claimed an enormous number of lives worldwide.Theranostics, combining diagnostic methods with personalized therapeutic approaches, shows huge potential to advance the battle against cancer.This review aims provide overview theranostics oncology: exploring its history, current advances, challenges, prospects.We present fundamental evolution from radiotherapeutics, cellular therapeutics, nanotherapeutics, showcasing critical milestones last decade.From early concept targeted drug delivery emergence medicine, benefited advances imaging technologies, molecular biology, nanomedicine.Furthermore, we emphasize pertinent illustrations that revolutionary strategies cancer management enhance accuracy therapies customized for individual patients, thereby facilitating implementation medicine.Finally, describe future perspectives on emerging topics, field.

Language: Английский

Citations

16
Synergistic Glutathione Depletion and STING Activation to Potentiate Dendritic Cell Maturation and Cancer Vaccine Efficacy DOI
Jianping Liu, Ye Zhang,

Bowei Yang

et al.

Angewandte Chemie International Edition, Journal Year: 2024, Volume and Issue: 63(10)

Published: Jan. 10, 2024

Dendritic cell (DC) maturation and antigen presentation are key factors for successful vaccine-based cancer immunotherapy. This study developed manganese-based layered double hydroxide (Mn-LDH) nanoparticles as a self-adjuvanted vaccine carrier that not only promoted DC through synergistically depleting endogenous glutathione (GSH) activating STING signaling pathway, but also facilitated the delivery of model ovalbumin (OVA) into lymph nodes subsequent in DCs. Significant therapeutic-prophylactic efficacy OVA-loaded Mn-LDH (OVA/Mn-LDH) nanovaccine was determined by tumor growth inhibition mice bearing B16-OVA tumor. Our results showed OVA/Mn-LDH could be potent system development without need adjuvant. Therefore, combination GSH exhaustion pathway activation might an advisable approach promoting presentation, finally improving efficacy.

Language: Английский

Citations

15
Intrinsic immunomodulatory hydrogels for chronic inflammation DOI

Yuna Qian,

Jiayi Ding,

Rui Zhao

et al.

Chemical Society Reviews, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

This tutorial review presents the development of advanced immunomodulatory hydrogels strategically designed to address chronic inflammation through their intrinsic properties.

Language: Английский

Citations

14
Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges DOI Creative Commons
Xiao-kun Zhang, Ye Wu, Jia-Yi Lin

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2024, Volume and Issue: 14(9), P. 3818 - 3833

Published: May 13, 2024

Immunotherapies hold immense potential for achieving durable potency and long-term survival opportunities in cancer therapy. As vital biological mediators, peptides with high tissue penetration superior selectivity offer significant promise enhancing immunotherapies (CITs). However, physicochemical peptide features such as conformation stability pose challenges to their on-target efficacy. This review provides a comprehensive overview of recent advancements therapeutic targeting key steps the cancer-immunity cycle (CIC), including tumor antigen presentation, immune cell regulation, checkpoint signaling. Particular attention is given associated these boosting CIC within context clinical progress. Furthermore, possible future developments this field are also discussed provide insights into emerging CITs robust efficacy safety profiles.

Language: Английский

Citations

10